Biodrogaspa.lt - Company finances
|
EUR
|
2018
From: 2018-03-20
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 13,064 | 34,735 | 46,761 | 43,207 | 37,836 | 44,737 | 32,969 | 36,498 |
| Profit before tax | 704 | 991 | 2,903 | 80 | 328 | 494 | -2,308 | 196 |
| Net profit | 669 | 941 | 2,758 | 76 | 312 | 469 | -2,308 | 192 |
| Equity | 1,169 | 2,110 | 4,868 | 4,944 | 5,256 | 5,725 | 3,417 | 3,608 |
| Liabilities | - | - | - | - | 4,633 | 4,562 | 6,440 | 3,261 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current assets | 3,365 | 4,470 | 10,660 | 6,748 | 9,889 | 10,287 | 9,857 | 6,869 |
| Total assets | 3,365 | 4,470 | 10,660 | 6,748 | 9,889 | 10,287 | 9,857 | 6,869 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 4,069 | 2,993 | 686 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | +165.9% | +34.6% | -7.6% | -12.4% | +18.2% | -26.3% | +10.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 19.9% | 21.1% | 25.9% | 1.1% | 3.2% | 4.6% | -23.4% | 2.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 57.2% | 44.6% | 56.7% | 1.5% | 5.9% | 8.2% | -67.5% | 5.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 5.1% | 2.7% | 5.9% | 0.2% | 0.8% | 1.0% | -7.0% | 0.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 5.4% | 2.9% | 6.2% | 0.2% | 0.9% | 1.1% | -7.0% | 0.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 0.9 | 0.8 | 1.9 | 0.9 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Biodrogaspa.lt - Social security debts
The company had no debts to Sodra
Biodrogaspa.lt - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Biodrogaspa.lt is: 1 €
| From | To | Overdue, € |
|---|---|---|
| 2026-06-18 | 2026-09-02 | 1.29 |
| 2025-04-02 | 2026-02-16 | 1.29 |
| 2025-03-23 | 2025-04-01 | 1.2 |
| 2025-02-28 | 2025-03-20 | 1.2 |
| 2025-01-30 | 2025-02-19 | 1.2 |
| 2024-12-30 | 2025-01-15 | 1.2 |
| 2024-11-28 | 2024-12-23 | 1.2 |
| 2024-10-28 | 2024-11-18 | 1.2 |
| 2024-09-29 | 2024-10-16 | 1.2 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Biodrogaspa.lt, MB (code 304796505) is a Small partnership engaged in other non-specialised retail sale. In 2025, the company generated revenue of €36.5K, up 10.7% year on year, and returned to profitability with net profit of €192 after a loss of €2.3K in 2024. Profit margin in 2025 was 0.5%, indicating a very thin but positive result. The three-year trend shows a decline from €44.7K revenue and €469 net profit in 2023, a weaker 2024, and a modest recovery in 2025. On the balance sheet, total assets decreased to €6.9K at the end of 2025, while equity stood at €3.6K and liabilities at €3.3K. The equity ratio was 52.5%, and debt-to-equity was 0.90, suggesting a relatively balanced capital structure. Return on equity was 5.3% and return on assets 2.8%, while asset turnover reached 5.31x, reflecting a high level of revenue relative to the asset base.